

# Positron Emission Tomography

---

Peter E. Valk, Dominique Delbeke, Dale L. Bailey,  
David W. Townsend, and Michael N. Maisey (*Eds*)

---

# **Positron Emission Tomography**

## **Clinical Practice**

With 256 Figures  
including 131 in Color

 Springer


Peter E. Valk, MB, BS, FRACP  
Northern California PET Imaging Center  
Sacramento, CA, USA

Dominique Delbeke, MD, PhD  
Professor and Director of Nuclear  
Medicine  
Positron Emission Tomography  
Department of Radiology and  
Radiological Sciences  
Vanderbilt University Medical Center  
Nashville, TN, USA

Dale L. Bailey, PhD  
Associate Professor of Medicine  
Department of Nuclear Medicine  
Royal North Shore Hospital  
Sydney, Australia

David W. Townsend, PhD  
Director  
Cancer Imaging and Tracer Development  
Program  
The University of Tennessee Medical  
Center  
Knoxville, TN, USA

Michael N. Maisey, BSc, MD, FRCR, FRCP  
Professor of Emeritus  
Department of Radiological Sciences  
Guy's and St Thomas' Clinical PET  
Centre  
Guy's and St Thomas' Hospital Trust  
London, UK

Artwork and tables marked with  symbol throughout the book are original to the 1st edition (Valk PE, Bailey DL, Townsend DW, Maisey MN. Positron Emission Tomography: Basic Science and Clinical Practice. Springer-Verlag London Ltd. 2003) and are being republished in this edition.

British Library Cataloguing in Publication Data  
Positron emission tomography : clinical practice  
1. Tomography, Emission  
I. Valk, Peter E., 1940–  
616'.07575  
ISBN-10: 1852339713

Library of Congress Control Number: 2005932896

ISBN-10: 1-85233-971-3      e-ISBN 1-84628-187-3  
ISBN-13: 978-1-85233-971-5

Printed on acid-free paper.

© Springer-Verlag London Limited 2006

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patents Act 1988, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the publishers, or in the case of reprographic reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency. Enquiries concerning reproduction outside those terms should be sent to the publishers.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore free for general use.

Product liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

Printed in China (EXPO/EVB)

9 8 7 6 5 4 3 2 1

Springer Science+Business Media  
springer.com

# Foreword

---

The use of positron emission tomography (PET) in clinical practice is key to the successful management of many patients with a wide variety of diseases. Whereas in the 1980s and 1990s nuclear medicine physicians struggled to convince other doctors about the potential clinical value of PET, it is now a challenge to keep up with the requests of our clinical colleagues for the various applications of PET. In fact, in most cases the barriers are now related to reimbursement for a given PET procedure. At the time this foreword was written, many FDG/PET procedures are reimbursable, and the U.S. National PET Registry, which is about to be implemented, will allow FDG/PET imaging data to accumulate on rare tumors, while allowing for Center for Medicare and Medicaid Services (CMS) reimbursement. The challenges are now shifting toward solving some of the limitations of FDG/PET through the use of next generation instrumentation and newer tracers that hold the promise of improving on what is already a remarkable achievement with FDG/PET.

It is my hope that there will in fact be an enormous growth of nuclear medicine driven by new imaging tracers that will fuel a growing number of clinical applications. Many failures will occur in order to give rise to the next generation of PET imaging tracers, but these failures are necessary on the road to a better tomorrow. Perhaps a “Super FDG” will be born out of these efforts, along with very specific imaging tracers useful for very select groups of patients. Technology will continue to drive our ability to identify new cellular targets, new molecular imaging agents against those targets, and the routine high-throughput synthesis and use of those new imaging tracers. Just as PET/CT has markedly influenced the growth of FDG/PET, newer technologies will likely come into play. The debut of MR-PET, molecular imaging technologies such as molecular optical imaging, and many other technologies will likely change the landscape of nuclear medicine forever. To keep the correct perspective we must remember that it is not about the technologies per se, but really about optimal patient care. We must not slip into the future, but plan for the future so we maximize our ability to help patients through the power of nuclear medicine and molecular imaging. However technologies and new tracers evolve, the concepts of interrogation at the cellular and molecular level will continue to define the evolution of nuclear medicine and the interception of disease processes through functional imaging.

The use of PET and PET/CT in patient care is best learned from clinicians at the leading edge of imaging who also routinely interpret the images. This excellent book put together by leading clinicians, who have helped the field of PET to get to the current stage, is an enormous educational resource. It is very thorough with clear examples and covers all major aspects of PET/CT application in patient management. Someday, technologies will surely evolve so that authors will be seen and speak to us virtually and interactively through “digital books.” For now we must be content to learn from the best teachers through their words and image examples on paper. This book is the next best thing to having all the contributing authors virtually teaching the student about all aspects of PET/CT. Till the day that digital interactive books arrive, I plan on keeping this book nearby.

Sanjiv Sam Gambhir MD, PhD  
Stanford University

# Preface

---

Peter E. Valk passed away on December 16, 2003 in Berkeley, California. David Townsend wrote in the “*In Memoriam*” that was published in the February 2004 issue of the *Journal of Nuclear Medicine*: “He will be deeply missed by his many friends and colleagues throughout the Nuclear Medicine and PET community world-wide for his insight, knowledge, integrity and humour.”

Peter was a dear friend and we certainly miss him. In 2003, Peter coedited *Positron Emission Tomography: Basic Science and Clinical Practice*, a comprehensive contemporary reference textbook on positron emission tomography (PET). A few months before he died, Peter informed me that Springer intended to divide this nearly 900 pages textbook into two separate volumes for clinical and basic sciences. Peter was acutely aware of his prognosis and asked me if I would be willing to take over and edit the clinical volume. I willingly accepted. This book *Positron Emission Tomography: Clinical Practice* is a selected and updated version of the clinical chapters from the original book.

Positron Emission Tomography is an exceptional functional imaging tool. There has been a tremendous increase in interest in PET in the past decade, not only as a research tool but particularly in the clinical arena. The editors of the original book (Peter Valk, Dale Bailey, David Townsend and Michael Maisey) noted how they had collectively been involved in many aspects of PET development, including instrumentation, algorithms and protocol developments and applications, as well as the training of basic scientists and medical specialists, and efforts to convince health bureaucrats of the value of functional imaging in patient management. Through their extensive involvement in all aspects of PET, they progressively became aware of the lack of a comprehensive and contemporary reference work covering the science and clinical applications of PET. The original edition of their book arose from a desire to redress this situation.

The field of PET is progressing rapidly with the developments of multimodality imaging using integrated PET/CT systems. For this separate edition of clinical applications, the intent remains true to the aims of the first edition, namely, to provide a contemporary reference work covering the science and clinical applications of PET with extensive updating to include PET/CT technology. The book is designed to be used by residents and fellows training in medical imaging specialties as well as imaging experts in private or academic medicine who need to become familiar with this technology, and by those whose specialties carry over to PET and PET/CT such as oncologists, cardiologists, neurologists and surgeons.

Chapters 1 to 4 address the basic aspects of PET and PET/CT including physics and instrumentation, an overview of the clinical advantages of the PET/CT technology over PET or CT alone; the viewpoint of the technologist, radiation dosimetry and protection. Chapters 5 to 25 address oncologic applications and have been significantly updated with new data related to the PET/CT technology; many PET/CT illustrations are included. As in the first edition, a chapter is devoted to infectious diseases and another to PET imaging in pediatric disorders. Chapter 26 is an overview of the cardiac applications of PET, and Chapter 27 discusses cardiac PET/CT that some experts envision as the future one-stop-shop cardiac examination. Chapter 28 is an overview of PET imaging in clinical neurology and is probably the least influenced by recent development of PET/CT technology.

To conclude, I restate part of the preface from the first edition:

We are indebted to the many friends and colleagues who have contributed to this book, and who have willingly shared their knowledge and experience.

The functional nature of PET is based on its ability to target specific biochemical pathways through sophisticated radioactive probes and to record the time course of tracer uptake with highly sensitive instrumentation. PET is indeed a rich area in which to work, in part because of the multidisciplinary nature of the field. Developments in instrumentation, for example, are as much driven by radiochemistry and medical challenges as they are by progress in basic physics and instrumentation. Manufacturers of PET instrumentation have also played a major role in the development of the field by sharing many of their designs for critical appraisal at an early stage, and by being willing to listen to, support, and often fund novel prototype concepts. The development of the combined PET/CT scanner is a prime example of this collaboration.

PET is currently moving forward rapidly on a number of fronts: instrumentation is developing at a fast pace; synthetic radiochemistry is becoming more sophisticated and reliable; new reconstruction algorithms and processing methods are becoming more generally usable because of rapid advances in computer hardware and software; clinical applications are burgeoning as PET becomes affordable for more practitioners; and developments in molecular biology and functional genomics provide opportunities for monitoring gene expression and targets for gene therapy.

In this context, it is a challenge to produce a reference work which remains current even during the period from production of the original text to eventual publication, let alone for a significant number of years afterwards. We leave it up to the reader, and to future readers, to assess how successful we have been in this endeavour.

Dominique Delbeke, MD, PhD  
December 2005

# Contents

---

Contributors . . . . .	xi
1 Basic Science of PET and PET/CT <i>David W. Townsend</i> . . . . .	1
2 Incremental Value of Imaging Structure and Function <i>Dominique Delbeke</i> . . . . .	17
3 The Technologist's Perspective <i>Bernadette F. Cronin</i> . . . . .	27
4 Radiation Protection and Dosimetry in PET and PET/CT <i>Jocelyn E.C. Towson and Stefan Eberl</i> . . . . .	41
5 Artifacts and Normal Variants in Whole-Body PET and PET/CT Imaging <i>Gary J.R. Cook</i> . . . . .	63
6 PET Imaging in Brain Tumors <i>Terence Z. Wong and R. Edward Coleman</i> . . . . .	79
7 PET and PET/CT Imaging in Lung Cancer <i>Pierre Rigo, Roland Hustinx, and Thierry Bury</i> . . . . .	89
8 PET and PET/CT Imaging in Head and Neck Cancer <i>Val J. Lowe, Brendan C. Stack, Jr., and Trond V. Bogsrud</i> . . . . .	107
9 PET and PET/CT Imaging in Lymphoma <i>Guy H.M. Jerusalem, Roland Hustinx, and Pierre Rigo</i> . . . . .	125
10 PET and PET/CT Imaging in Colorectal Cancer <i>Christiaan Schiepers and Peter E. Valk</i> . . . . .	147
11 PET and PET/CT Imaging in Esophageal and Gastric Cancers <i>Farrokh Dehdashti and Barry A. Siegel</i> . . . . .	165
12 PET and PET/CT Imaging in Tumors of the Pancreas and Liver <i>Dominique Delbeke and William H. Martin</i> . . . . .	181
13 PET and PET/CT Imaging in Breast Cancer <i>Richard L. Wahl</i> . . . . .	197
14 PET and PET/CT Imaging in Testicular and Gynecologic Cancers <i>Sharon F. Hain</i> . . . . .	217
15 PET and PET/CT Imaging in Melanoma <i>George M. Segall and Susan M. Swetter</i> . . . . .	233

16	PET and PET/CT Imaging in Urologic Tumors <i>Paul D. Shreve . . . . .</i>	243
17	PET and PET/CT Imaging in Sarcoma <i>Michael J. O'Doherty and Michael A. Smith . . . . .</i>	253
18	PET and PET/CT Imaging in Thyroid and Adrenal Diseases <i>I. Ross McDougall . . . . .</i>	269
19	PET and PET/CT Imaging in Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias <i>Ronald C. Walker, Laurie B. Jones-Jackson, Erik Rasmussen, Marisa Miceli, Edgardo J.C. Angtuaco, Frits Van Rhee, Guido J. Tricot, Joshua Epstein, Elias J. Anaissie, and Bart Barlogie . . . . .</i>	283
20	Evolving Role of FDG-PET Imaging in the Management of Patients with Suspected Infection and Inflammatory Disorders <i>Hongming Zhuang and Abass Alavi . . . . .</i>	303
21	PET Imaging of the Skeleton <i>Gary J.R. Cook, Ignac Fogelman, and Ora Israel . . . . .</i>	317
22.	PET Imaging in Pediatric Disorders <i>Hossein Jadvar, Leonard P. Connolly, Frederic H. Fahey, and Barry L. Shulkin . . . . .</i>	337
23	PET Imaging for Tumor Hypoxia: Characterizing the Tumor and Guiding Treatment <i>Joseph G. Rajendran and Kenneth A. Krohn . . . . .</i>	359
24	Labeled Pyrimidines in PET Imaging <i>Anthony F. Shields. . . . .</i>	375
25	Assessment of Treatment Response by FDG-PET <i>Lale Kostakoglu and Peter E. Valk . . . . .</i>	387
26	PET in Clinical Cardiology <i>Frank M. Bengel and Markus Schwaiger. . . . .</i>	413
27	Assessment of Coronary Artery Disease with Cardiac PET/CT <i>Marcelo F. Di Carli . . . . .</i>	433
28	PET in Clinical Neurology <i>Yen F. Tai and Paola Piccini . . . . .</i>	453
	Index . . . . .	463



# Contributors

---

Abass Alavi, MD  
Department of Radiology  
Division of Nuclear Medicine  
Hospital of the University of  
Pennsylvania  
Philadelphia, PA, USA

Elias J. Anaissie, MD  
Myeloma Institute for Research and  
Therapy  
University of Arkansas for Medical  
Sciences  
Little Rock, AR, USA

Edgardo J.C. Angtuaco, MD  
Section of Neuroradiology  
Department of Radiology  
University of Arkansas for Medical  
Sciences  
Little Rock, AR, USA

Dale L. Bailey, PhD  
Associate Professor of Medicine  
Department of Nuclear Medicine  
Royal North Shore Hospital  
Sydney, Australia

Bart Barlogie, MD, PhD  
Myeloma Institute for Research and  
Therapy  
University of Arkansas for Medical  
Sciences  
Little Rock, AR, USA

Frank M. Bengel, MD  
Nuklearmedizinische Klinik  
Technische Universität München  
München, Germany

Trond V. Bogsrud, MD  
Department of Medical Imaging  
Division of Nuclear Medicine  
University Clinic  
The Norwegian Radium Hospital  
Oslo, Norway

Thierry Bury, MD, PhD  
Division of Pulmonary Medicine  
Department of Medicine  
University Hospital of Liège, Sart-Tilman  
Liège, Belgium

R. Edward Coleman, MD  
Department of Radiology  
Division of Nuclear Medicine  
Duke University Medical Center  
Durham, NC, USA

Leonard P. Connolly, MD  
Department of Radiology  
Division of Nuclear Medicine  
Children's Hospital  
Boston, MA, USA

Gary J.R. Cook, MBBS, MSc, MD, FRCP,  
FRCR  
Department of Nuclear Medicine and PET  
Royal Marsden Hospital  
Sutton, UK

Bernadette F. Cronin, DCR (R), DRI,  
FETC  
Department of Nuclear Medicine and PET  
The Royal Marsden Hospital  
Sutton, UK

Farrokh Dehdashti, MD  
Division of Nuclear Medicine  
Edward Mallinckrodt Institute of  
Radiology  
Washington University School of  
Medicine  
St. Louis, MO, USA

Dominique Delbeke, MD, PhD  
Professor and Director of Nuclear  
Medicine  
Positron Emission Tomography  
Department of Radiology and  
Radiological Sciences  
Vanderbilt University Medical Center  
Nashville, TN, USA

Marcelo F. Di Carli, MD  
Department of Radiology  
Division of Nuclear Medicine/PET  
Brigham and Women's Hospital  
Harvard Medical School  
Boston, MA, USA

Stefan Eberl, BE, MSc, PhD  
Department of PET & Nuclear Medicine  
Royal Prince Alfred Hospital  
Sydney, Australia

Joshua Epstein, DSc  
Myeloma Institute for Research and  
Therapy  
University of Arkansas for Medical  
Sciences  
Little Rock, AR, USA

Frederic H. Fahey, DSc  
Department of Radiology  
Division of Nuclear Medicine  
Children's Hospital  
Boston, MA, USA

Ignac Fogelman, MD, FRCP  
Department of Nuclear Medicine  
Guy's and St Thomas' Hospital  
Guy's and St Thomas' Hospital Trust  
London, UK

Sharon F. Hain, BSc, MBBS, FRACP  
Institute of Nuclear Medicine  
Middlesex Hospital  
UCH NHS Trust and Hammersmith  
Hospitals NHS Trust  
London, UK

Roland Hustinx, MD  
Division of Nuclear Medicine  
Department of Medicine  
University Hospital of Liège,  
Sart-Tilman  
Liège, Belgium

Ora Israel, MD  
Department of Nuclear Medicine  
Rambam Medical Center  
Haifa, Israel

Hossein Jadvar, MD, PhD, FACNM  
Department of Radiology  
Division of Nuclear Medicine  
Keck School of Medicine  
University of Southern California  
Los Angeles, CA, USA

Guy H.M. Jerusalem, MD, PhD  
Division of Medical Oncology  
Department of Medicine  
University Hospital of Liège,  
Sart-Tilman  
Liège, Belgium

Laurie B. Jones-Jackson, MD  
Department of Radiology  
University of Arkansas for Medical  
Sciences  
Little Rock, AR, USA

Lale Kostakoglu, MD  
Department of Radiology  
Division of Nuclear Medicine  
The New York Presbyterian Hospital  
Weill Medical College of Cornell  
University  
Weill Cornell Medical Center  
New York, NY, USA

Kenneth A. Krohn, PhD  
Departments of Radiology and  
Radiation Oncology  
University of Washington  
Seattle, WA, USA

Val J. Lowe, MD  
Department of Radiology  
Division of Nuclear Medicine  
Mayo Clinic  
Rochester, MN, USA

Michael N. Maisey, BSc, MD, FRCR,  
FRCP  
Professor of Emeritus  
Department of Radiological Sciences  
Guy's and St Thomas' Clinical PET  
Centre  
Guy's and St Thomas' Hospital Trust  
London, UK

William H. Martin, MD  
Department of Radiology and  
Radiological Sciences  
Vanderbilt University Medical Center  
Nashville, TN, USA

I. Ross McDougall, MBChB, MD, PhD,  
FRCP  
Division of Nuclear Medicine  
Stanford University Medical Center  
Stanford, CA, USA

Marisa Miceli, MD  
Myeloma Institute for Research and  
Therapy  
University of Arkansas for Medical  
Sciences  
Little Rock, AR, USA

Michael J. O'Doherty, MA, MSc, MD,  
FRCP  
Department of Nuclear Medicine  
Clinical PET Centre  
Guy's, King's and St Thomas' School of  
Medicine  
Guys and St Thomas' NHS Trust  
St Thomas' Hospital  
London, UK

Paola Piccini, MD, PhD  
Division of Neurosciences and Mental  
Health  
Imperial College School of Medicine  
Hammersmith Hospital  
London, UK

Joseph G. Rajendran, MD  
Division of Nuclear Medicine  
University of Washington Medical  
Center  
Seattle, WA, USA

Erik Rasmussen, MS  
Cancer Research and Biostatistics  
Seattle, WA, USA

Pierre Rigo, MD, PhD  
Department of Nuclear Medicine  
Centre Hospitalier Princesse Grace  
Monaco

Christiaan Schiepers, MD, PhD  
Molecular and Medical Pharmacology  
David Geffen School of Medicine  
at UCLA  
Los Angeles, CA, USA

Markus Schwaiger, MD  
Nuklearmedizinische Klinik  
Technische Universität München  
München, Germany

George M. Segall, MD  
Nuclear Medicine Services  
Veterans Affairs Palo Alto Health Care  
System, Palo Alto CA, and  
Department of Radiology  
Stanford University School of Medicine  
Stanford, CA, USA

Anthony F. Shields, MD, PhD  
Department of Internal Medicine  
Karmanos Cancer Institute  
Wayne State University  
Detroit, MI, USA

Paul D. Shreve, MD  
Advanced Radiology Services PC  
Grand Rapids, MI, USA

Barry L. Shulkin, MD, MBA  
Division of Diagnostic Imaging  
St. Jude's Children's Research Hospital  
Memphis, TN, and  
Division of Nuclear Medicine  
Department of Radiology  
University of Michigan Medical Center  
Ann Arbor, MI, USA

Barry A. Siegel, MD  
Division of Nuclear Medicine  
Edward Mallinckrodt Institute of  
Radiology  
Washington University School of  
Medicine  
St. Louis, MO, USA

Michael A. Smith, MA, MB BChir, FRCS  
Department of Orthopaedics  
The St Thomas' Soft Tissue Tumor Unit  
Guys and St Thomas' NHS Trust  
Guy's Hospital  
London, UK

Brendan C. Stack, Jr., MD, FACS  
Division of Otolaryngology, Head and  
Neck Surgery  
Pennsylvania State University College of  
Medicine and Milton S. Hershey  
Medical Center  
Hershey, PA, USA

Susan M. Swetter, MD  
Dermatology Services  
Veterans Affairs Palo Alto Health Care  
System, Palo Alto CA, and  
Department of Dermatology  
Stanford University School of Medicine  
Stanford, CA, USA

Yen F. Tai, MB BS, MRCP  
Division of Neurosciences and Mental  
Health  
Imperial College School of Medicine  
Hammersmith Hospital  
London, UK

David W. Townsend, PhD  
Director  
Cancer Imaging and Tracer  
Development Program  
The University of Tennessee Medical  
Center  
Knoxville, TN, USA

Jocelyn E.C. Towson, MA, MSc  
Department of PET & Nuclear Medicine  
Royal Prince Alfred Hospital  
Sydney, Australia

Guido J. Tricot, MD, PhD  
University of Arkansas for Medical  
Sciences  
Myeloma Institute for Research and  
Therapy  
Little Rock, AR, USA

†Peter E. Valk, MB, BS, FRACP  
Northern California PET Imaging  
Center  
Sacramento, CA, USA

Frits Van Rhee, MD, PhD  
Myeloma Institute for Research and  
Therapy  
University of Arkansas for Medical  
Sciences  
Little Rock, AR, USA

Richard L. Wahl, MD  
The Johns Hopkins PET Center  
Russell H. Morgan Department of  
Radiology and Radiological Science  
Johns Hopkins University (JHU)  
School of Medicine  
Baltimore, MD, USA

Ronald C. Walker, MD  
Department of Radiology  
University of Arkansas for Medical  
Sciences  
Little Rock, AR, USA

Terence Z. Wong, MD, PhD  
Department of Radiology  
Division of Nuclear Medicine  
Duke University Medical Center  
Durham, NC, USA

Hongming Zhuang, MD, PHD  
Department of Radiology  
Division of Nuclear Medicine  
Hospital of the University of  
Pennsylvania  
Philadelphia, PA, USA

† Deceased.

Abstract: This tutorial explains how positron emission tomography (PET) imaging systems generate 3-D medical images. The article details how the PET system detects gamma-rays produced when injected doped sugars react differently to affected tissue. The article also discusses how competing electrical noise in the environment affects imaging, and why it is important to accurately detect photon timing and movement so the signal generated within the patient can be localized. We review positron-emission tomography (PET), which has inherent advantages that avoid the shortcomings of other nuclear medicine imaging methods. PET image reconstruction methods with origins in signal and image processing are discussed, including the potential problems of these methods. A summary of statistical image reconstruction methods, which can yield improved image quality, is also presented. Positron emission tomography (PET) is a functional imaging technique that uses radioactive substances known as radiotracers to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption. Different tracers are used for various imaging purposes, depending on the target process within the body. For example,  $^{18}\text{F}$ -FDG is commonly used to detect cancer,  $^{18}\text{F}$ -NaF is widely used for detecting bone formation, and Positron emission tomography (PET) is a type of nuclear medicine procedure that measures metabolic activity of the cells of body tissues. PET is actually a combination of nuclear medicine and biochemical analysis. Used mostly in patients with brain or heart conditions and cancer, PET helps to visualize the biochemical changes taking place in the body, such as the metabolism (the process by which cells change food into energy after food is digested and absorbed into the blood) of the heart muscle.